文献速递前列腺癌

放疗后2年前列腺活检的价值:MRC RT01试验启示

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
PubMed 文献 · Eur Urol · 2018-01-04

基于MRC RT01随机试验,843例局限期前列腺癌患者随机接受64Gy或74Gy适形放疗联合3-6个月新辅助雄激素剥夺治疗,其中312例在放疗后2年接受前列腺活检。

要点

  • 2年活检阳性较阴性/可疑者后续bPFS更差,HR=4.81(95%CI 2.50-9.26,p<0.001)。
  • 活检阳性与总生存估计无显著差异,HR=1.58(95%CI 0.52-4.78,p=0.42)。
  • 2年PSA 1.01-2.09ng/ml较≤1.0ng/ml与后续PSA失败相关,HR=2.71。

核心结论

  • 放疗后2年前列腺活检对PSA控制良好的患者价值有限,但活检阳性与较高PSA状态均与未来bPFS事件强相关。
  • 选择性活检策略可能为早期挽救干预提供机会。

研究设计与样本

  • MRC RT01随机试验,1998-2001年入组843例局限期前列腺癌男性,随机接受对照64Gy或增量74Gy适形放疗,联合3-6个月新辅助雄激素剥夺治疗。
  • 计划于适格男性自适形放疗开始起2年时行前列腺活检,312/843例实际接受活检。

主要发现

  • 活检时中位PSA为0.5ng/ml。
  • 共报告64例bPFS事件:活检阴性者46/145(32%)、可疑者6/18(33%)、阳性者12/14(86%)。
  • 活检阳性较阴性及可疑活检预示后续bPFS更差,HR=4.81(95%CI 2.50-9.26,p<0.001)。
  • 活检阳性与生存的估计为HR=1.58(95%CI 0.52-4.78,p=0.42)。
  • 2年PSA 1.01-2.09ng/ml较PSA≤1.0ng/ml与后续PSA失败(HR=2.71,95%CI 1.98-3.71)、bPFS事件(HR=2.45,95%CI 1.81-3.32)及前列腺癌特异性生存(HR=2.87,95%CI 1.08-7.64)相关。

临床怎么用

  • 不推荐常规行放疗后2年活检,但对治疗后PSA水平不理想且适合早期挽救治疗的选定患者可考虑活检。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The importance of 2-yr postradiotherapy prostate biopsy status remains uncertain. OBJECTIVE: To assess the value of 2 year post treatment biopsies in a randomised trial of radiotherapy dose escalation. DESIGN, SETTING, AND PARTICIPANTS: Between 1998 and 2001, 843 men with localised prostate cancer were randomised to receive either control-64Gy or escalated-74Gy conformal radiotherapy (CFRT) in the MRC RT01 trial in combination with 3-6-mo neoadjuvant androgen deprivation therapy. Prostate biopsies were planned at 2 yr from start of CFRT in suitable men. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prostate biopsy results and prostate-specific antigen (PSA) levels performed at 2 yr post-CFRT were evaluated with long-term biochemical progression free survival (bPFS) and overall survival. Outcome measures were timed from the 2-yr biopsy using a landmark approach. RESULTS AND LIMITATIONS: A 2-yr biopsy was performed in 312/843 patients. One hundred and seventy-seven patients were included in the per-protocol group with median follow-up of 7.8 yr from biopsy. Median PSA at biopsy was 0.5ng/ml. Sixty-four bPFS events were reported: 46/145 (32%) in patients with negative, 6/18 (33%) suspicious, and 12/14 (86%) positive biopsies. A positive biopsy was prognostic of worse bPFS, going forward, compared with negative and suspicious biopsies, hazard ratio (HR)=4.81 (95% confidence interval [CI]: 2.50-9.26, p<0.001). The estimate for survival was HR=1.58 (95% CI: 0.52-4.78, p=0.42). PSA values at 2 yr between 1.01ng/ml and 2.09ng/ml were also associated with subsequent PSA failures (HR=2.71, 95% CI: 1.98-3.71), bPFS events (HR=2.45, 95% CI: 1.81-3.32), and prostate cancer-specific survival (HR=2.87, 95% CI: 1.08-7.64) compared with PSA ≤1.0ng/ml. CONCLUSIONS: Two-year postradiotherapy prostate biopsies have limited value in patients with PSA control but both positive biopsy and higher PSA status are strongly associated with future bPFS events. A policy of selected biopsy may provide an opportunity for early salvage interventions. PATIENT SUMMARY: Routine 2-yr postradiotherapy biopsy is not recommended but can be considered in selected patients with unfavourable post-treatment prostate-specific antigen levels who are suitable for early salvage treatments.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kass-Iliyya A, Jovic G, Murphy C, et al. Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial. Eur Urol. 2018. PMID: 29307509. doi:10.1016/j.eururo.2017.12.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。